![]() |
市场调查报告书
商品编码
1402481
2030 年亚太地区深脑模拟市场预测 - 区域分析 - 按产品、应用和最终用户Asia Pacific Deep Brain Simulation Market Forecast to 2030 - Regional Analysis - by Product, Application, and End User |
亚太地区深脑模拟市场预计将从2022年的9,835万美元成长到2030年的1.8804亿美元。预计2022年至2030年CAGR为8.4%。
深部脑部刺激的技术进步和批准推动亚太地区深部脑部模拟市场
机器人植入、多目标刺激、改进的微电极设计、可充电脉衝产生器以及个人化、有针对性的程式都是深部脑部刺激 (DBS) 领域的技术进步。由于这些进步,与传统方法相比,DBS 设备在帕金森氏症患者中显示出更少的副作用、更高的疗效和症状缓解。 Abbott 的 Infinity 脑深部刺激系统是一种技术先进的新型 DBS,可帮助患者控制症状。它是第一个无线 iOS 软体 DBS 行动平台,可提供高效、个人化的治疗管理,并降低副作用风险。根据 2020 年 2 月发布的 MGM Healthcare 新闻稿,泰米尔纳德邦 MGM Healthcare 首次针对强迫症 (OCD) 进行了深部脑部刺激 (DBS)。因此,DBS 的技术进步预计将在预测期内为亚太地区深部脑部刺激市场创造机会。
亚太地区深脑模拟市场概况
中国是世界上老年人口最多的国家。根据《柳叶刀》发表的题为「中国人口老化:危机还是机会?」的研究报告。 2019年,中国60岁以上人口约2.54亿人。到 2040 年,这一数字预计将增至 4.02 亿,约占总人口的 28%。随着非传染性疾病的风险和负担随着对卫生和社会保健系统的需求的增加而增加,这些变化对该国的公共卫生产生了深远的影响。帕金森氏症(PD)是我国常见的神经退化性疾病。根据《中国日报》报道,截至 2023 年 2 月,中国约有 400 万名帕金森氏症患者,65 岁以上族群中约有 1.7% 被诊断出患有此疾病。根据《健康、人口和营养杂誌》上讨论的一项研究,中国患有阿兹海默症的人数约为 600 万,其中 65 岁、75 岁和 85 岁人群的痴呆率为 5%,分别为11.5% 和30%。丘脑底核 (STN) 的深部脑部刺激 (DBS) 可有效治疗巴金森氏症 (PD)。随着DBS硬体的进步,研究人员开发了多种新颖的程式技术,其中远端程式设计在中国已广泛应用。自2018年以来,我们一直使用PINS产品(中国北京PINS医疗有限公司)为患有PD的患者进行远端编程。对于患有晚期帕金森氏症(超过 15 年)的患者,DBS 被认为是一种高效的治疗选择。然而,与任何其他已开发国家不同,如果无法报销,DBS 仍然会给患者带来巨大的经济负担。在中国,手术费用主要由患者的健康保险承担,但 DBS 硬体的费用仅涵盖部分,这可能会阻碍该国市场的成长。
亚太地区深脑模拟市场营收及 2030 年预测(百万美元)
亚太地区深脑模拟市场区隔
亚太地区深脑模拟市场分为产品、应用、最终用户和国家。
根据产品,亚太地区深部脑部模拟市场分为单通道深部脑部刺激器、双通道深部脑部刺激器以及软体和配件。 2022年,双通道深部脑部刺激器细分市场在亚太深部脑部模拟市场中占据最大份额。
根据应用,亚太地区深部脑部模拟市场分为帕金森氏症、震颤、肌张力失调、癫痫、阿兹海默症等。 2022年,帕金森氏症领域在亚太深部脑部模拟市场中占据最大份额。
根据最终用户,亚太地区深部脑部模拟市场分为医院、神经科诊所、门诊手术中心等。 2022年,医院领域在亚太深部脑部模拟市场中占据最大份额。
依国家/地区划分,亚太地区深度脑模拟市场分为中国、日本、印度、韩国、澳洲和亚太地区其他地区。 2022年,中国市场在亚太深脑模拟市场中占据最大份额。
Abbott Laboratories、北京品思医疗有限公司、波士顿科学公司、Medtronic Plc 和 SceneRay Co Ltd 是亚太地区深脑模拟市场的一些领先公司。
The Asia Pacific deep brain simulation market is expected to grow from US$ 98.35 million in 2022 to US$ 188.04 million by 2030. It is estimated to grow at a CAGR of 8.4% from 2022 to 2030.
Technological Advancements and Approvals in Deep Brain Stimulation Drive Asia Pacific Deep Brain Simulation Market
Robotic implantation, multi-target stimulation, improved microelectrode designs, rechargeable pulse generators, and personalized, targeted programming are among the technological advancements in deep brain stimulation (DBS). Owing to these advancements, DBS devices show fewer side effects and improved efficacy and symptom relief in Parkinson's patients compared to traditional methods. Abbott's Infinity Deep Brain Stimulation System is a technologically advanced new DBS that helps the patients manage their symptoms. It is the first wireless iOS software DBS mobile platform that has offered efficient and personalized therapy management with reduced risk of side effects. According to the MGM Healthcare press release published in February 2020, MGM Healthcare, Tamil Nadu, performed its first deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD). Therefore, technological advancements in DBS are expected to create opportunities for the Asia Pacific deep brain stimulation market during the forecast period.
Asia Pacific Deep Brain Simulation Market Overview
China is home to the world's largest population of older adults. According to a study published in The Lancet titled "China's Aging Population: Crisis or Opportunity?" in 2019, people in China aged 60 or older were ~254 million. By 2040, that number is expected to rise to 402 million, ~28% of the population. These changes have profound public health implications in the country as the risk and burden of noncommunicable diseases increase along with the demand for health and social care systems. Parkinson's disease (PD) is a common neurodegenerative disease in the country. According to ChinaDaily, there were approximately 4 million Parkinson's patients in China as of February 2023, and ~1.7% of people over 65 years have been diagnosed with the disease. According to a study discussed in the Journal of Health, Population, and Nutrition, the number of people with Alzheimer's disease in China is ~6 million, with dementia rates among 65-, 75-, and 85-year-olds being 5%, 11.5%, and 30%, respectively. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective in the treatment of Parkinson's disease (PD). With advancements in DBS hardware, researchers have developed several novel programming technologies, of which remote programming is widely used in China. Since 2018, we have been performing remote programming for patients suffering from PD using PINS products (PINS Medical, Ltd., Beijing, China). For patients with advanced Parkinson's disease (over a 15-year time horizon), DBS is considered to be a highly effective treatment option. However, DBS remains a significant economic burden on the patient when not reimbursed, unlike in any other developed country. In China, the surgery cost is mainly covered by the patient's health insurance, but the cost of DBS hardware is only partially covered, which can hamper the growth of the market in the country.
Asia Pacific Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Deep Brain Simulation Market Segmentation
The Asia Pacific deep brain simulation market is segmented into product, application, end user, and country.
Based on product, the Asia Pacific deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. In 2022, the dual channel deep brain stimulator segment registered the largest share in the Asia Pacific deep brain simulation market.
Based on application, the Asia Pacific deep brain simulation market is segmented into Parkinson's disease, tremor, dystonia, epilepsy, Alzheimer's disease, and others. In 2022, the Parkinson's disease segment registered the largest share in the Asia Pacific deep brain simulation market.
Based on end user, the Asia Pacific deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the largest share in the Asia Pacific deep brain simulation market.
Based on country, the Asia Pacific deep brain simulation market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. In 2022, China segment registered the largest share in the Asia Pacific deep brain simulation market.
Abbott Laboratories, Beijing PINS Medical Co Ltd, Boston Scientific Corp, Medtronic Plc, and SceneRay Co Ltd are some of the leading companies operating in the Asia Pacific deep brain simulation market.